CRISPR company Arbor raises $73.9M to test therapy in clinical trials

Ar­bor Biotech­nolo­gies, a start­up found­ed by CRISPR pi­o­neer Feng Zhang nine years ago, has closed a $73.9 mil­lion Se­ries C fi­nanc­ing to bring its first …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.